[go: up one dir, main page]

MA52809A - Inhibiteurs de sarm1 - Google Patents

Inhibiteurs de sarm1

Info

Publication number
MA52809A
MA52809A MA052809A MA52809A MA52809A MA 52809 A MA52809 A MA 52809A MA 052809 A MA052809 A MA 052809A MA 52809 A MA52809 A MA 52809A MA 52809 A MA52809 A MA 52809A
Authority
MA
Morocco
Prior art keywords
sarm1 inhibitors
sarm1
inhibitors
Prior art date
Application number
MA052809A
Other languages
English (en)
Inventor
Jonathan Bentley
Todd Bosanac
Andrew Simon Brearley
Rajesh Devraj
Robert Owen Hughes
Richard Andrew Jarjes-Pike
Original Assignee
Disarm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disarm Therapeutics Inc filed Critical Disarm Therapeutics Inc
Publication of MA52809A publication Critical patent/MA52809A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA052809A 2018-06-07 2019-06-06 Inhibiteurs de sarm1 MA52809A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862682045P 2018-06-07 2018-06-07

Publications (1)

Publication Number Publication Date
MA52809A true MA52809A (fr) 2021-04-14

Family

ID=68770684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052809A MA52809A (fr) 2018-06-07 2019-06-06 Inhibiteurs de sarm1

Country Status (8)

Country Link
US (1) US12448374B2 (fr)
EP (1) EP3801499B1 (fr)
JP (1) JP7478142B2 (fr)
CN (1) CN112839648B (fr)
CA (1) CA3102598A1 (fr)
ES (1) ES2988933T3 (fr)
MA (1) MA52809A (fr)
WO (1) WO2019236884A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
JP2021527125A (ja) 2018-06-07 2021-10-11 ディサーム・セラピューティクス・インコーポレイテッドＤｉｓａｒｍ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｓａｒｍ１阻害剤
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3123215C (fr) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs
WO2021050913A1 (fr) 2019-09-12 2021-03-18 Disarm Therapeutics, Inc. Inhibiteurs de sarm1
EP4065714A1 (fr) * 2019-11-26 2022-10-05 Disarm Therapeutics, Inc. Méthodes et compositions pour la neuroprotection
CN116075511B (zh) * 2020-04-09 2024-10-29 达萨玛治疗公司 作为sarm1抑制剂的稠合吡唑衍生物
CN115916764B (zh) 2020-04-09 2024-09-20 达萨玛治疗公司 作为sarm1抑制剂的吲唑衍生物
TWI786777B (zh) * 2020-08-24 2022-12-11 美商達薩瑪治療公司 Sarm1之抑制劑
KR20250121164A (ko) * 2022-11-12 2025-08-11 캠브리지 엔터프라이즈 리미티드 치료법 및 화장품에 사용하기 위한 sarm1 제제
WO2024222835A1 (fr) * 2023-04-27 2024-10-31 Sironax Ltd. Modulateurs de sarm1, préparations et leurs utilisations
CN116836162B (zh) * 2023-05-24 2025-09-05 南方医科大学 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138552A3 (fr) * 1983-10-17 1986-03-19 Eli Lilly And Company Préparation de 3-biclyclipyridinium-méthyl céphalosporines
US5468757A (en) * 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
WO2000026211A1 (fr) * 1998-10-30 2000-05-11 Merck & Co., Inc. Inhibiteurs de la thrombine
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
CN101310771B (zh) 2001-04-11 2012-08-08 千寿制药株式会社 视觉功能障碍改善剂
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
EP1432707B1 (fr) 2001-10-02 2012-03-28 Pharmacia & Upjohn Company LLC Composes d'heteoraryle fusionne substitues par azabicyclo utiles pour le traitement de maladies
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
PT1483265E (pt) 2002-03-05 2007-01-31 Lilly Co Eli Derivados de purina como inibidores de quinase
AU2003241925A1 (en) 2002-05-31 2003-12-19 Eisai R&D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
MXPA05004723A (es) 2002-11-01 2005-12-05 Pharmacia & Upjohn Co Llc Compuestos que tienen ambas actividades del agonista alfa 7 nachr y el antagonista 5ht para el tratamiento de las enfermedades del snc.
AU2003269413A1 (en) 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
CA2508004A1 (fr) 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Traitement de maladies a l'aide de combinaisons d'agonistes du recepteur nicotinique de l'acetylcholine alpha 7 et d'autres composes
OA12969A (en) 2002-12-11 2006-10-13 Pharmacia & Upjohn Co Llc Combination for the treatment of ADHD.
EP1587511A2 (fr) 2003-01-22 2005-10-26 Pharmacia & Upjohn Company LLC Traitement de maladies l'aide d'agonistes totaux du récepteur nicotinique de l'acetycholine (achr) alpha-7
US20070185079A1 (en) 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
US7932389B2 (en) 2004-07-21 2011-04-26 Merck Serono S.A. Octahydropyrrolo[2,3C]pyridine derivatives and pharmaceutical use thereof
DK1784404T3 (da) 2004-09-03 2012-02-13 Yuhan Corp Pyrrolo[2,3-c]pyridinderivater samt fremgangsmåder til deres fremstilling
CA2589127C (fr) 2004-12-08 2013-02-05 Johannes Gutenberg-Universitat Mainz Derives de 3-(indolyl)-4-arylmaleimide et utilisation comme inhibiteurs de l'angiogenese
JP5065908B2 (ja) 2004-12-24 2012-11-07 プロシディオン・リミテッド Ｇタンパク質結合受容体作動薬
EP1879896A1 (fr) 2005-04-05 2008-01-23 Eli Lilly And Company Composes d' imidazopyridazine
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
DK1906965T3 (en) 2005-06-22 2015-08-03 Chemocentryx Inc Azaindazol compounds and methods of use thereof
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
CN101003537A (zh) 2006-01-17 2007-07-25 上海恒瑞医药有限公司 吡咯并哒嗪类衍生物及其制备方法和用途
GB0705803D0 (en) 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
JP5427769B2 (ja) 2007-03-30 2014-02-26 サノフイ Ｐｇｄｓ阻害剤としてのピリミジンヒドラジド化合物
JP2010524931A (ja) 2007-04-16 2010-07-22 メルク・シャープ・エンド・ドーム・コーポレイション 二環式アニリドヘテロ環式ｃｇｒｐ受容体アンタゴニスト
WO2009041567A1 (fr) 2007-09-27 2009-04-02 Banyu Pharmaceutical Co., Ltd. Dérivè de diaryl kétimine à activité antagoniste sur le récepteur de l'hormone de concentration de la mélanine
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2280968A2 (fr) 2008-03-24 2011-02-09 Medivation Technologies, Inc. Pyrido [3,4-b]indoles et leurs procédés d'utilisation
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
BRPI0917540A2 (pt) 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
ATE542813T1 (de) 2008-08-06 2012-02-15 Pfizer 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
WO2010042337A1 (fr) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Nouveaux dérivés de 6-azaindole aminopyrimidine ayant une activité inhibitrice de nik
JP5529876B2 (ja) 2008-10-17 2014-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物
WO2010046780A2 (fr) 2008-10-22 2010-04-29 Institut Pasteur Korea Composés antiviraux
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
SI3050874T1 (sl) 2008-11-14 2019-04-30 Merial Inc. Enantiomerno obogatene ariloazol-2-il cianoetilamino paraziticidne spojine
JP2011178779A (ja) 2010-02-04 2011-09-15 Daiichi Sankyo Co Ltd イミダゾピリジン−２−オン誘導体
WO2011096490A1 (fr) 2010-02-04 2011-08-11 第一三共株式会社 Dérivé d'imidazopyridin-2-one
EP2534156A1 (fr) 2010-02-11 2012-12-19 OSI Pharmaceuticals, LLC Dérivés de la 7-aminofuropyridine
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
EP2632898A4 (fr) 2010-10-29 2014-04-02 Biogen Idec Inc Inhibiteurs de tyrosine kinase hétérocycliques
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
WO2012093101A1 (fr) 2011-01-04 2012-07-12 Novartis Ag Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
WO2012106343A2 (fr) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Inhibiteurs de hdac et procédés thérapeutiques les utilisant
WO2012114252A1 (fr) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Nouveaux amides d'indole et de pyrrolopyridine
EA201391239A1 (ru) 2011-04-05 2014-03-31 Пфайзер Лимитед Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
WO2012178022A2 (fr) 2011-06-24 2012-12-27 University Of Massachusetts Applications thérapeutiques ciblant sarm1
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
TWI577671B (zh) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN102532027A (zh) 2012-03-01 2012-07-04 常州协丰医药研发有限公司 一种通过羟胺活化来形成吲唑衍生物的合成方法
CN102675310B (zh) 2012-05-09 2014-12-24 林辉 制备吡唑并芳杂环化合物的方法
US20150336948A1 (en) 2012-05-29 2015-11-26 Merck Sharp & Dohme Corp. Isotopically Labeled Biaryl Urea Compounds
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
KR20150036481A (ko) 2012-07-12 2015-04-07 노파르티스 아게 보체 경로 조절제 및 그의 용도
PL2877467T3 (pl) 2012-07-26 2017-08-31 Glaxo Group Limited 2-(azaindolo-2-ylo)benzoimidazole jako inhibitory pad4
SG11201507383WA (en) 2013-03-12 2015-10-29 Abbvie Inc Dihydro-pyrrolopyridinone bromodomain inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
ES2637816T3 (es) 2013-05-02 2017-10-17 Pfizer Inc. Derivados de imidazo-triazina como inhibidores de PDE10
GB201310460D0 (en) * 2013-06-12 2013-07-24 Lytix Biopharma As Compounds
FR3008975A1 (fr) 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN106413707A (zh) * 2014-02-25 2017-02-15 艾其林医药公司 用于治疗补体介导的疾病的酰胺化合物
JP6581111B2 (ja) 2014-04-28 2019-09-25 メッドシャイン ディスカバリー インコーポレイテッド Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体
US9796713B2 (en) 2014-06-13 2017-10-24 Bristol-Myers Squibb Company Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2015188368A1 (fr) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo [2,3-c] pyridines en tant qu'agents d'imagerie d'enchevêtrements neurofibrillaires
EP3154973B1 (fr) 2014-06-13 2018-03-21 Bristol-Myers Squibb Company Composés tricyliques utilisés comme ligands du récepteur nicotinique alpha-7 de l'acétylcholine
EP3705482B1 (fr) 2014-08-06 2023-02-22 California Institute of Technology Silylation d'hétérocycles aromatiques par des catalyseurs abondants sur terre, exempts de métaux de transition
KR102500071B1 (ko) 2014-10-23 2023-02-14 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 화합물
CN107074882B (zh) 2014-10-23 2019-07-30 詹森药业有限公司 作为nik抑制剂的新的吡唑并嘧啶衍生物
WO2016095089A1 (fr) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Inhibiteurs d'erk
WO2016095088A1 (fr) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Inhibiteurs d'erk
WO2016100157A2 (fr) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Antagonistes octahydropyrrolopyridines 6,5-bicycliques du récepteur d'orexine
WO2016161571A1 (fr) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Inhibiteurs de la btk de type indazole et azaindazole
AU2016261031A1 (en) 2015-05-13 2017-10-05 Selvita S.A. Substituted quinoxaline derivatives
AU2016294450A1 (en) 2015-07-13 2017-12-07 Arvinas Operations, Inc. Alanine-based modulators of proteolysis and associated methods of use
AU2016303558B2 (en) 2015-08-05 2020-08-06 Indivior Uk Limited Dopamine D3 receptor antagonists having a bicyclo moiety
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340982B1 (fr) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Composés pour le traitement de troubles immunitaires et inflammatoires
EP3389664A4 (fr) 2015-12-14 2020-01-08 Raze Therapeutics Inc. Inhibiteurs de caféine de mthfd2 et leurs utilisations
JP2019501222A (ja) 2016-01-07 2019-01-17 シーエス ファーマテック リミテッド Ｅｇｆｒチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
TWI854164B (zh) 2016-02-01 2024-09-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
ES2788348T3 (es) 2016-05-24 2020-10-21 Merck Patent Gmbh Derivados heterocíclicos tricíclicos
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
WO2018011628A1 (fr) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Composés inhibiteurs thérapeutiques
EP3500285B1 (fr) 2016-08-16 2022-04-20 Henry Ford Health System Compositions pour le traitement de la douleur neuropathique induite par la chimiothérapie
MA46191A (fr) 2016-09-09 2021-04-21 Incyte Corp Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
WO2018057989A1 (fr) 2016-09-24 2018-03-29 Washington University Inhibiteurs de l'activité sarm1 nadase et utilisations de ceux-ci
EP3526222B1 (fr) 2016-10-14 2022-08-17 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
US10947242B2 (en) 2016-11-02 2021-03-16 Janssen Pharmaceutica, Nv [1,2,4]triazolo[1,5and#8208;A]pyrimidine compounds as PDE2 inhibitors
WO2018149986A1 (fr) 2017-02-16 2018-08-23 Oryzon Genomics, S.A. Dérivés de 2-(bicyclo-hétéroaryl)-isonicotinique en tant qu'inhibiteurs d'histone déméthylase
US20200131142A1 (en) 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
JP7174709B2 (ja) 2017-03-15 2022-11-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
WO2018170173A1 (fr) 2017-03-15 2018-09-20 Metacrine, Inc. Agonistes du récepteur farnésoïde x et leurs utilisations
WO2018210229A1 (fr) 2017-05-18 2018-11-22 南京明德新药研发股份有限公司 Agoniste du récepteur nicotinique de l'acétylcholine alpha-7 et application de celui-ci
WO2019034890A1 (fr) 2017-08-18 2019-02-21 Cancer Research Technology Limited Composés pyrrolo[2,3-b]pyridine et leur utilisation dans le traitement du cancer
WO2019106087A1 (fr) 2017-11-29 2019-06-06 Syddansk Universitet Inhibiteurs d'ampk
CA3118400A1 (fr) 2017-12-01 2019-06-06 The Board Of Trustees Of The University Of Illinois Modificateurs epigenetiques a base de pyridinone et leurs utilisations
IL274973B2 (en) 2017-12-05 2024-07-01 Oryzon Genomics Sa 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
EP3752150A1 (fr) 2018-02-16 2020-12-23 UCB Biopharma SRL Dérivés cycliques 6,5 hétérobicycliques pharmaceutiques
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
JP2019182784A (ja) 2018-04-10 2019-10-24 大日本住友製薬株式会社 ジヒドロピラゾロピラジノン誘導体
US11505543B2 (en) 2018-04-11 2022-11-22 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
US11882759B2 (en) 2018-04-13 2024-01-23 Universal Display Corporation Organic electroluminescent materials and devices
CA3099318C (fr) 2018-05-09 2024-02-13 Aprinoia Therapeutics Inc. Composes heteroaryles et leurs utilisations
JP2021527125A (ja) 2018-06-07 2021-10-11 ディサーム・セラピューティクス・インコーポレイテッドＤｉｓａｒｍ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｓａｒｍ１阻害剤
CN112867489A (zh) 2018-06-07 2021-05-28 达萨玛治疗公司 Sarm1抑制剂
BR112021002408A2 (pt) 2018-08-09 2021-05-04 Valo Early Discovery, Inc. carboxamidas como inibidores da protease específica de ubiquitina

Also Published As

Publication number Publication date
EP3801499A1 (fr) 2021-04-14
WO2019236884A1 (fr) 2019-12-12
JP2021528488A (ja) 2021-10-21
EP3801499A4 (fr) 2022-01-12
CA3102598A1 (fr) 2019-12-12
US12448374B2 (en) 2025-10-21
CN112839648B (zh) 2025-04-04
US20220194933A1 (en) 2022-06-23
CN112839648A (zh) 2021-05-25
EP3801499B1 (fr) 2024-02-28
JP7478142B2 (ja) 2024-05-02
ES2988933T3 (es) 2024-11-22

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
MA54550A (fr) Inhibiteurs de kif18a
EP4007752C0 (fr) Inhibiteurs de kif18a
EP4007753C0 (fr) Inhibiteurs de kif18a
EP3801503A4 (fr) Inhibiteurs de sarm1
IL269196A (en) Novel inhibitors
EP3843714A4 (fr) Inhibiteurs de cd73
DK3740479T3 (da) Dna-pk-hæmmere
EP3788042A4 (fr) Inhibiteurs de bcl-2
MA52413A (fr) Inhibiteurs de cd73
MA53287A (fr) Inhibiteurs de prmt5
EP3541932A4 (fr) Inhibiteurs de crispr-cas9
IL304348A (en) Cd73 inhibitors
MA52813A (fr) Inhibiteurs de sarm1
EP3801499A4 (fr) Inhibiteurs de sarm1
MA52635A (fr) Inhibiteurs de magl
DK3571192T3 (da) Jak1-selektive inhibitorer
EP3817736A4 (fr) Inhibiteurs de pikfyve
PT3746446T (pt) Inibidores de prc2
EP3980011A4 (fr) Inhibiteurs de sarm1
EP3773537A4 (fr) Inhibiteurs de stat3
EP3706747A4 (fr) Inhibiteurs de prmt5
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3833664A4 (fr) Inhibiteurs de smad3
EP3833669A4 (fr) Inhibiteurs de prmt5